Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Verschoor

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
International Journal of Pharmaceutics: X|July 6, 2023
Heparin interferes with the uptake of liposomes in gliomaThomas S van Solinge, Kristina Pagh Friis, Killian O'Brien, et al.
Nature Communications|July 30, 2025
Long-term effect of temporary ART initiated during primary HIV-1 infection on viral persistenceAlexander O Pasternak, Pien M van Paassen, Yara L Verschoor, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2019
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockadeMohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, et al.
Nature|October 20, 2025
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancersPedro B Tan, Yara L Verschoor, José G van den Berg, et al.
The New England Journal of Medicine|June 5, 2024
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon CancerMyriam Chalabi, Yara L Verschoor, Pedro Batista Tan, et al.
Nature Medicine|September 15, 2024
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trialPeter G M de Gooyer, Yara L Verschoor, Lauren D W van den Dungen, et al.
Nature Medicine|January 8, 2024
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trialYara L Verschoor, Joris van de Haar, José G van den Berg, et al.
Nature Medicine|March 6, 2024
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trialYara L Verschoor, Joris van de Haar, José G van den Berg, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
International Journal of Pharmaceutics: X|July 6, 2023
Heparin interferes with the uptake of liposomes in gliomaThomas S van Solinge, Kristina Pagh Friis, Killian O'Brien, et al.
Nature Communications|July 30, 2025
Long-term effect of temporary ART initiated during primary HIV-1 infection on viral persistenceAlexander O Pasternak, Pien M van Paassen, Yara L Verschoor, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2019
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockadeMohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, et al.
Nature|October 20, 2025
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancersPedro B Tan, Yara L Verschoor, José G van den Berg, et al.
The New England Journal of Medicine|June 5, 2024
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon CancerMyriam Chalabi, Yara L Verschoor, Pedro Batista Tan, et al.
Nature Medicine|September 15, 2024
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trialPeter G M de Gooyer, Yara L Verschoor, Lauren D W van den Dungen, et al.
Nature Medicine|January 8, 2024
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trialYara L Verschoor, Joris van de Haar, José G van den Berg, et al.
Nature Medicine|March 6, 2024
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trialYara L Verschoor, Joris van de Haar, José G van den Berg, et al.
Pageof 6